New from the Diagnosing Health Care Podcast: Knock, knock! If the Drug Enforcement Administration (DEA) is already at your door, it may be too late.
Enforcement is on the rise, and the microscope is fixed on controlled substances. What can industry stakeholders do to prevent penalties and protect themselves from DEA scrutiny?
On this episode, Epstein Becker Green attorneys Melissa Jampol, David Johnston, and Avery Schumacher discuss recent and pending updates to DEA rules and guidance, outline steps stakeholders can take to prepare for an inspection, and share tips on what to do when the DEA arrives.
As of September 25, 2023, Bill A4151 was approved by the New Jersey Senate and is now law in New Jersey. This approved bill amends the existing New Jersey recreational cannabis regulatory landscape. Bill A4151, or P.L. 2023, c.162, (the “Amendment”) revises and waives certain restrictions currently imposed on owners of cannabis establishments. Prior to the enactment of the Amendment, Class 5 retail license holders and their owners, were prohibited from holding interest in other Class 5 retail licenses because horizontal expansion is otherwise prohibited under the state’s ...
Blog Editors
Recent Updates
- HHS OIG Issues Favorable Advisory Opinion Regarding Surgical Supply Discounts to Ambulatory Surgery Centers in Exchange for Software Purchases
- Health Care Workplace Violence Legislation Heats Up in 2026
- DOGE's Attempt to Crowdsource Medicaid Fraud Scrutiny: Is This the Future of Healthcare Fraud Investigations?
- Feds vs. the States: Dr. Mehmet Oz Announces an Investigation Into New York’s Medicaid Program
- U.S. Supreme Court to Weigh Induced Infringement Case Regarding ‘Generic Version of Vascepa®’